Vitiligo during dupilumab therapy
Vincenzo Picone, Maddalena Napolitano, Ginevra Torta, Gabriella Fabbrocini, Cataldo Patruno
Abstract
Dupilumab, which is a fully human anti–interleukin (IL)-4 receptor α monoclonal antibody, inhibits both IL-4 and IL-13 signaling.1 It is approved for the treatment of moderate-to-severe atopic dermatitis (AD), asthma, and chronic rhinosinusitis with nasal polyps, as well as recently for prurigo nodularis, showing efficacy and good long-term safety profile in clinical trials and real-life studies.2-4 Despite these data, a number of recent publications have reported various adverse events.2 Injection-site reactions are the most commonly reported adverse events, followed by ophthalmic complications (dry eyes, conjunctivitis, blepharitis, and keratitis), paradoxical head and neck erythema (“dupilumab red face”), onset of psoriatic lesions, progression of cutaneous T-cell lymphoma, alopecia areata, and arthritis.